Board Change • May 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Director Elodie Carr-Cingari was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Declared Dividend • Apr 19
Dividend of CHF0.40 announced Shareholders will receive a dividend of CHF0.40. Ex-date: 28th April 2026 Payment date: 30th April 2026 Dividend yield will be 0.5%, which is lower than the industry average of 0.9%. Announcement • Mar 27
Siegfried Holding AG, Annual General Meeting, Apr 14, 2026 Siegfried Holding AG, Annual General Meeting, Apr 14, 2026, at 10:00 W. Europe Standard Time. Reported Earnings • Feb 22
Full year 2025 earnings released: EPS: CHF3.85 (vs CHF3.71 in FY 2024) Full year 2025 results: EPS: CHF3.85 (up from CHF3.71 in FY 2024). Revenue: CHF1.33b (up 2.6% from FY 2024). Net income: CHF168.7m (up 5.4% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 8% per year. Announcement • Feb 21
Siegfried Announces Management Changes Siegfried will consolidate the Chief Operating Officer roles currently split between Drug Substances and Drug Products into one position. In this context, Henrik Krüpper will be stepping down from his responsibilities as Chief Operating Officer Drug Substances to pursue opportunities outside the company, effective March 1, 2026. Stefan Randl has been appointed ad interim Chief Operating Officer Drug Substances in addition to his role as Chief Scientific Officer until a Chief Operating Officer is appointed. Announcement • Feb 09
Siegfried Holding AG to Report First Half, 2026 Results on Aug 21, 2026 Siegfried Holding AG announced that they will report first half, 2026 results on Aug 21, 2026 Announcement • Jan 28
Siegfried Holding AG (SWX:SFZN) signed binding agreement to acquire Purisys, LLC from SKCP Catalyst Fund I, fund managed by SK Capital Partners, LP and Noramco, Inc. Siegfried Holding AG (SWX:SFZN) signed binding agreement to acquire Purisys, LLC from SKCP Catalyst Fund I, fund managed by SK Capital Partners, LP and Noramco, Inc. on January 27, 2026. Given Siegfried’s strong balance sheet, the acquisition will be financed through existing and new debt instruments. In separate related transactions, Siegfried Holding AG also signed binding agreements to acquire Noramco and Extractas Bioscience. Following the close of the transaction, SK Capital will retain ownership of Halo Pharmaceuticals.
The transaction is subject to customary closing conditions and regulatory approvals. The expected completion of the transaction is in late 2026. The valuation of the acquired business is below 10 times Enterprise Value / EBITDA.
Jefferies Financial Group Inc., RBC Capital Markets, LLC and Rothschild & Co US Inc. acted as financial advisors for Noramco, Inc. Kirkland & Ellis LLP acted as legal advisor for Noramco, Inc. The team of Cravath, Swaine & Moore LLP led by G.J. Ligelis Jr., Daniel J. Cerqueira and Ryan J. Wichtowski, Lauren Angelilli, Eric W. Hilfers, David J. Kappos, Carys J. Webb, Margaret T. Segall, Matthew Morreale, Joyce Law, Brian M. Budnick, Crawford Rundlett and Jesús Saracho acted as legal advisor for Siegfried Holding AG. New Risk • Jan 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swiss stocks, typically moving 3.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Share price has been volatile over the past 3 months (3.6% average weekly change). Valuation Update With 7 Day Price Move • Jan 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CHF100.00, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 29x in the Life Sciences industry in Switzerland. Total returns to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF94.10 per share. Announcement • Sep 04
Siegfried Holding AG to Report Fiscal Year 2025 Results on Feb 20, 2026 Siegfried Holding AG announced that they will report fiscal year 2025 results on Feb 20, 2026 Major Estimate Revision • Aug 28
Consensus EPS estimates increase by 13% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from CHF3.53 to CHF3.98. Revenue forecast steady at CHF1.36b. Net income forecast to grow 17% next year vs 37% growth forecast for Life Sciences industry in Switzerland. Consensus price target broadly unchanged at CHF112. Share price was steady at CHF84.30 over the past week. Reported Earnings • Aug 24
First half 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First half 2025 results: EPS: CHF1.50 (down from CHF1.68 in 1H 2024). Revenue: CHF619.5m (flat on 1H 2024). Net income: CHF65.8m (down 8.3% from 1H 2024). Profit margin: 11% (down from 12% in 1H 2024). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 6.6%. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year. Major Estimate Revision • Jul 01
Consensus EPS estimates fall by 11% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from CHF3.90 to CHF3.48 per share. Revenue forecast steady at CHF1.36b. Net income forecast to grow 5.4% next year vs 19% growth forecast for Life Sciences industry in Switzerland. Consensus price target broadly unchanged at CHF114. Share price fell 4.3% to CHF89.80 over the past week. Board Change • May 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Director Elodie Carr-Cingari was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Apr 27
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 4.1% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks High level of debt (46% net debt to equity). Paying a dividend despite having no free cash flows. Declared Dividend • Apr 14
Dividend increased to CHF3.80 Dividend of CHF3.80 is 5.6% higher than last year. Ex-date: 22nd April 2025 Payment date: 24th April 2025 Dividend yield will be 0.4%, which is lower than the industry average of 0.9%. Announcement • Mar 24
Siegfried Holding AG, Annual General Meeting, Apr 10, 2025 Siegfried Holding AG, Annual General Meeting, Apr 10, 2025, at 10:00 W. Europe Standard Time. Reported Earnings • Feb 19
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: CHF37.14 (up from CHF26.59 in FY 2023). Revenue: CHF1.29b (up 1.8% from FY 2023). Net income: CHF160.1m (up 42% from FY 2023). Profit margin: 12% (up from 8.9% in FY 2023). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.3%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 30
Siegfried Holding AG to Report First Half, 2025 Results on Aug 21, 2025 Siegfried Holding AG announced that they will report first half, 2025 results on Aug 21, 2025 Buy Or Sell Opportunity • Jan 15
Now 21% overvalued Over the last 90 days, the stock has fallen 17% to CHF965. The fair value is estimated to be CHF796, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings are also forecast to grow by 13% per annum over the same time period. New Risk • Aug 25
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 40% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company. Announcement • Aug 22
Siegfried Holding AG to Report Fiscal Year 2024 Results on Feb 18, 2025 Siegfried Holding AG announced that they will report fiscal year 2024 results on Feb 18, 2025 Announcement • Aug 20
Siegfried Holding AG to Report First Half, 2024 Results on Aug 22, 2024 Siegfried Holding AG announced that they will report first half, 2024 results on Aug 22, 2024 Announcement • Jul 02
Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc. Siegfried Holding AG (SWX:SFZN) agreed to acquire early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc. on June 12, 2024. The acquisition is financed from existing funds. the transaction is subject to customary closing conditions and is expected to close by July 1, 2024.Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc on july 1, 2024. As part of the acquisition, all projects at the Grafton site have been transferred to Siegfried and the Siegfried Acceleration Hub will continue to fulfill all commitments to its existing customers. Reported Earnings • Feb 22
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: CHF26.59 (down from CHF37.07 in FY 2022). Revenue: CHF1.27b (up 3.4% from FY 2022). Net income: CHF112.7m (down 28% from FY 2022). Profit margin: 8.9% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Feb 20
Now 22% undervalued Over the last 90 days, the stock has risen 7.2% to CHF845. The fair value is estimated to be CHF1,079, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 41%. For the next 3 years, revenue is forecast to grow by 6.2% per annum. Earnings are also forecast to grow by 9.9% per annum over the same time period. Reported Earnings • Aug 23
First half 2023 earnings released: EPS: CHF13.15 (vs CHF14.85 in 1H 2022) First half 2023 results: EPS: CHF13.15 (down from CHF14.85 in 1H 2022). Revenue: CHF607.1m (up 3.5% from 1H 2022). Net income: CHF55.2m (down 12% from 1H 2022). Profit margin: 9.1% (down from 11% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • May 18
Siegfried Announces Executive Changes Siegfried announces two changes to its Executive Committee: Irene Wosgien, currently serving as Chief Operating Officer Drug Substances (COO DS), will take over the global responsibility as Chief Human Resources Officer (CHRO) from Arnoud Middel who will leave Siegfried end of June 2023. Henrik Krupper, currently CEO of HCS Group, will join Siegfried to become the new COO DS. Irene Wosgien will take over as CHRO on 1 July 2023 while Arnoud Middel will assist her during the transition and will continue to support key HR projects until the end of the year. Henrik Krupper will assume his role on 1 November 2023 at the latest. Until then and starting on 1 July 2023, Marcel Imwinkelried will lead the DS technical operations organization in parallel to his regular role as Chief Operating Officer Drug Products. Both, Irene Wosgien and Henrik Krupper, will serve as members of Siegfried's Executive Committee. Arnoud Middel joined Siegfried in 2011 and since then has successfully built a professional global HR function which has been instrumental to Siegfried's organizational development and strong growth over the years. After 12 years with the company, he decided to leave Siegfried in order to pursue private ventures and prepare them next chapters of his career. Henrik Krupper (52, German citizen) holds a diploma (Dipl.-Ing.) in mechanical engineering with a specialization in process engineering from the Technical University (RWTH) Aachen (Germany). After completing his studies, he started his career at Th. Goldschmidt AG as site excellence and production manager followed by positions with increasing operational and managerial responsibilities at Evonik Industries AG (formerly Degussa AG), City Solar AG, Q-Cells SE and Soltecture GmbH. In 2012, he joined HCS Group, an international specialty chemicals company based in Germany, as Managing Director and Chief Commercial Officer and was appointed to his current role of Chief Executive Officer of the company in 2019. Announcement • May 06
Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG. Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023.Siegfried Holding AG (SWX:SFZN) completed the acquisition of 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023. Reported Earnings • Feb 25
Full year 2022 earnings released: EPS: CHF37.07 (vs CHF22.73 in FY 2021) Full year 2022 results: EPS: CHF37.07 (up from CHF22.73 in FY 2021). Revenue: CHF1.23b (up 12% from FY 2021). Net income: CHF156.5m (up 64% from FY 2021). Profit margin: 13% (up from 8.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Nov 16
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 20%. The fair value is estimated to be CHF842, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 32%. For the next 3 years, revenue is forecast to grow by 5.9% per annum. Earnings is also forecast to grow by 8.8% per annum over the same time period. Buying Opportunity • Oct 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 6.1%. The fair value is estimated to be CHF837, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 32%. For the next 3 years, revenue is forecast to grow by 6.0% per annum. Earnings is also forecast to grow by 9.0% per annum over the same time period. Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment improved over the past week After last week's 15% share price gain to CHF818, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 37x in the Life Sciences industry in Switzerland. Total returns to shareholders of 119% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF833 per share. Buying Opportunity • Jul 12
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be CHF830, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 6.2% per annum. Earnings is also forecast to grow by 13% per annum over the same time period. Upcoming Dividend • Jun 23
Upcoming dividend of CHF3.20 per share Eligible shareholders must have bought the stock before 30 June 2022. Payment date: 04 July 2022. Payout ratio is a comfortable 14% but the company is paying out more than the cash it is generating. Trailing yield: 0.5%. Lower than top quartile of Swiss dividend payers (4.1%). Lower than average of industry peers (0.7%). Buying Opportunity • Jun 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be CHF805, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 5.6% per annum. Earnings is also forecast to grow by 12% per annum over the same time period. Buying Opportunity • May 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 7.1%. The fair value is estimated to be CHF809, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 5.9% per annum. Earnings is also forecast to grow by 12% per annum over the same time period. Price Target Changed • May 20
Price target decreased to CHF862 Down from CHF928, the current price target is an average from 10 analysts. New target price is 39% above last closing price of CHF619. Stock is down 25% over the past year. The company is forecast to post earnings per share of CHF27.64 for next year compared to CHF22.73 last year. Buying Opportunity • May 05
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be CHF836, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 6.0% per annum. Earnings is also forecast to grow by 12% per annum over the same time period. Buying Opportunity • Mar 07
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be CHF884, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% per annum over the last 3 years. Earnings per share has grown by 16% per annum over the last 3 years. Reported Earnings • Mar 01
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CHF22.73 (up from CHF14.68 in FY 2020). Revenue: CHF1.10b (up 31% from FY 2020). Net income: CHF95.6m (up 57% from FY 2020). Profit margin: 8.7% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 4.1%. Over the next year, revenue is forecast to grow 8.7%, compared to a 36% growth forecast for the pharmaceuticals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 27
Siegfried Holding AG to Report First Half, 2022 Results on Aug 18, 2022 Siegfried Holding AG announced that they will report first half, 2022 results on Aug 18, 2022